Banescu C.,University Med and Pharm Tg Mures |
Benedek I.,University Med and Pharm Tg Mures |
Duicu C.,University Med and Pharm Tg Mures |
Demian S.,University Med and Pharm Tg Mures |
Voidazan S.,University Med and Pharm Tg Mures
Revista Romana de Medicina de Laborator | Year: 2011
Myelodysplastic syndrome (MDS) represents a group of clonal hematological disorders characterized by ineffective hematopoiesis and an increased risk for transformation into acute leukemia. Our aim was to identify the chromosomal abnormalities in patients with myelodysplastic syndrome and to evaluate the prognostic value of cytogenetic findings. Twenty-five patients from the Hematology Clinics in Tg.Mureş, newly diagnosed with MDS, were included in the study. We carried out bone marrow cultures according to standard methods. We successfully analyzed the karyotype of 24 patients (96%) and identified 15 (62.5%) cases with chromosomal abnormalities. According to the cytogenetic risk status, 13 patients have been classified in the good, 7 in the intermediate and 4 in the poor risk group. Patients with abnormal karyotype exhibited a high tendency to evolve into the leukemic phase (33%), as compared with those with normal karyotype. There were significant differences in overall survival (OS) noted among patients who had a normal karyotype and patients who had chromosomal abnormalities (p=0.012). Taking into account our results we consider that patients with an abnormal karyotype had a shorter survival and higher risk of leukemic transformation than those with a normal karyotype. In conclusion, cytogenetic results have an important role in the diagnosis and identification of prognostic subgroups of MDS.